Establishing risk of human experimentation with drugs: lessons from TGN1412
- 1 October 2006
- journal article
- review article
- Published by Elsevier in The Lancet
- Vol. 368 (9544) , 1387-1391
- https://doi.org/10.1016/s0140-6736(06)69562-7
Abstract
No abstract availableThis publication has 22 references indexed in Scilit:
- TGN1412: Time to Change the Paradigm for the Testing of New PharmaceuticalsAlternatives to Laboratory Animals, 2006
- TGN1412—a regulator's perspectiveNature Biotechnology, 2006
- Co-stimulatory agonists as immunological adjuvantsVaccine, 2006
- London's disastrous drug trial has serious side effects for researchNature, 2006
- Regulation of Immune Responses by T CellsNew England Journal of Medicine, 2006
- Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention TrialNew England Journal of Medicine, 2005
- Protecting Research Subjects — The Crisis at Johns HopkinsNew England Journal of Medicine, 2002
- A Death in the Laboratory: The Politics of the Gelsinger AftermathMolecular Therapy, 2001
- Healthy volunteer studies in Great Britain: the results of a survey into 12 months activity in this field.British Journal of Clinical Pharmacology, 1989
- Clinically significant adverse effects in a Phase 1 testing programClinical Pharmacology & Therapeutics, 1978